-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2022-501547-33-01
11
2024-12-24
Acute myocarditis
-
2023-507332-20-00
9
2024-12-18
Dupuytren contracture
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-518092-62-00
5
2024-12-09
Adult critically ill patients requiring non-invasive (NIMV) or invasiv
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-518096-57-00
5
2024-11-11
Septic shock
-
2023-510429-14-00
4
2024-10-22
HER2-mutated or overexpressed/amplified solid tumours
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508429-29-00
4
2024-09-26
Progressive Pulmonary Fibrosis
-
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-503859-10-00
5
2024-08-12
Moderate to Severe Plaque Psoriasis
-
2023-504169-22-02
5
2024-07-31
Severe cardiac inflammation
-
2023-508482-32-00
5
2024-07-22
Neutropenias
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2023-508178-27-00
9
2024-07-10
Participants with Advanced KRASG12C-Mutated Solid Tumors